ECSP099482A - Preparación farmacéutica para reducir la endometriosis - Google Patents
Preparación farmacéutica para reducir la endometriosisInfo
- Publication number
- ECSP099482A ECSP099482A EC2009009482A ECSP099482A ECSP099482A EC SP099482 A ECSP099482 A EC SP099482A EC 2009009482 A EC2009009482 A EC 2009009482A EC SP099482 A ECSP099482 A EC SP099482A EC SP099482 A ECSP099482 A EC SP099482A
- Authority
- EC
- Ecuador
- Prior art keywords
- pharmaceutical composition
- endometriosis
- negative influence
- bone density
- pharmaceutical preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una composición farmacéutica para el tratamiento de endometriosis sin reducir la densidad ósea contiene un gestágeno con eficacia antiandrogénica, con preferencia 17a-cianometil-l7-ß-hidroxiestra-4,9-dien-3-ona (dienogest), acetato de ciproterona o acetato de cloromadinona en una dosis diaria que es como máximo el doble de la dosis inhibidora de la ovulación, junto con uno o varios excipientes/portadores farmacéuticamente aceptables. La composición farmacéutica según la invención produce tanto la reducción de la endometriosis como también la ausencia de influencia negativa sobre el metabolismo óseo y de la densidad ósea y al mismo tiempo puede mantener en una medida tolerable los efectos colaterales conocidos de los medicamentos convencionales (por ejemplo, sofocaciones, acné, influencia negativa del perfil lipídico). La composición farmacéutica es por ello apropiada para la aplicación a largo plazo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07004202A EP1977752A1 (de) | 2007-03-01 | 2007-03-01 | Pharmazeutische Zubereitung zur Verminderung der Endometriose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP099482A true ECSP099482A (es) | 2009-08-28 |
Family
ID=38045772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2009009482A ECSP099482A (es) | 2007-03-01 | 2009-07-03 | Preparación farmacéutica para reducir la endometriosis |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP1977752A1 (es) |
| JP (1) | JP2010520159A (es) |
| KR (1) | KR20090119829A (es) |
| CN (1) | CN101583364A (es) |
| AU (1) | AU2008221012A1 (es) |
| BR (1) | BRPI0806598A2 (es) |
| CA (1) | CA2673936A1 (es) |
| CO (1) | CO6190606A2 (es) |
| CR (1) | CR10912A (es) |
| DO (1) | DOP2009000171A (es) |
| EA (1) | EA200900829A1 (es) |
| EC (1) | ECSP099482A (es) |
| MA (1) | MA31162B1 (es) |
| MX (1) | MX2009007259A (es) |
| NZ (1) | NZ577761A (es) |
| SV (1) | SV2009003324A (es) |
| TN (1) | TN2009000263A1 (es) |
| WO (1) | WO2008104342A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101874806A (zh) * | 2009-04-29 | 2010-11-03 | 北京本草天源药物研究院 | 一种地诺孕素固体制剂 |
| CN102670519B (zh) * | 2011-03-16 | 2014-06-11 | 重庆莱美药业股份有限公司 | 一种可快速溶出的地诺孕素口服制剂及其制备方法 |
| CN103304619B (zh) * | 2013-06-08 | 2015-12-02 | 西藏海思科药业集团股份有限公司 | 一种地诺孕素化合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4426601A1 (de) * | 1994-07-27 | 1996-02-01 | Schering Ag | Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri |
| EP1535618A1 (en) * | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
| MY151322A (en) * | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
| DE102004026679A1 (de) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
| EP1655031A1 (de) * | 2004-10-08 | 2006-05-10 | Schering AG | Dienogest enthaltendes Langzeit-Verfahren zur Empfängnisverhütung |
-
2007
- 2007-03-01 EP EP07004202A patent/EP1977752A1/de not_active Withdrawn
-
2008
- 2008-02-23 MX MX2009007259A patent/MX2009007259A/es unknown
- 2008-02-23 EA EA200900829A patent/EA200900829A1/ru unknown
- 2008-02-23 CN CNA2008800023330A patent/CN101583364A/zh active Pending
- 2008-02-23 WO PCT/EP2008/001451 patent/WO2008104342A1/de active Application Filing
- 2008-02-23 BR BRPI0806598-5A patent/BRPI0806598A2/pt not_active IP Right Cessation
- 2008-02-23 CA CA002673936A patent/CA2673936A1/en not_active Abandoned
- 2008-02-23 NZ NZ577761A patent/NZ577761A/en not_active IP Right Cessation
- 2008-02-23 JP JP2009551120A patent/JP2010520159A/ja active Pending
- 2008-02-23 AU AU2008221012A patent/AU2008221012A1/en not_active Abandoned
- 2008-02-23 EP EP08707797A patent/EP2059248A1/de not_active Ceased
- 2008-02-23 KR KR1020097014169A patent/KR20090119829A/ko not_active Application Discontinuation
-
2009
- 2009-06-24 TN TNP2009000263A patent/TN2009000263A1/fr unknown
- 2009-07-03 SV SV2009003324A patent/SV2009003324A/es not_active Application Discontinuation
- 2009-07-03 CO CO09068629A patent/CO6190606A2/es not_active Application Discontinuation
- 2009-07-03 DO DO2009000171A patent/DOP2009000171A/es unknown
- 2009-07-03 EC EC2009009482A patent/ECSP099482A/es unknown
- 2009-07-03 CR CR10912A patent/CR10912A/es unknown
- 2009-08-04 MA MA32138A patent/MA31162B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1977752A1 (de) | 2008-10-08 |
| JP2010520159A (ja) | 2010-06-10 |
| CO6190606A2 (es) | 2010-08-19 |
| AU2008221012A1 (en) | 2008-09-04 |
| WO2008104342A1 (de) | 2008-09-04 |
| CR10912A (es) | 2009-08-13 |
| DOP2009000171A (es) | 2009-08-31 |
| KR20090119829A (ko) | 2009-11-20 |
| CA2673936A1 (en) | 2008-09-04 |
| NZ577761A (en) | 2012-03-30 |
| TN2009000263A1 (en) | 2010-10-18 |
| CN101583364A (zh) | 2009-11-18 |
| SV2009003324A (es) | 2009-10-02 |
| EP2059248A1 (de) | 2009-05-20 |
| MA31162B1 (fr) | 2010-02-01 |
| MX2009007259A (es) | 2009-07-10 |
| BRPI0806598A2 (pt) | 2014-05-06 |
| EA200900829A1 (ru) | 2010-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR115939A2 (es) | Composición que contiene palmitoil-etanolamida ultra-micronizada | |
| UY33343A (es) | Formas de dosificación sólidas orales con dosis muy bajas para la hrt | |
| CL2011003291A1 (es) | Composicion farmaceutica de dosis unica que contiene a) como gestageno 50-90 µg de levonorgestrel y b) como inhibidor cox (ciclooxigenasa) 5-60 mg de piroxicam, 50-600 mg de indometacina o 40-450 mg de diclofenaco; y su uso para preparar medicamentos para la anticoncepcion en caso de emergencia. | |
| NO20091954L (no) | Anvendelse av ostradiolvalerat eller 17ß-ostradil i kombinasjon med dienogest for oral terapi for opprettholdelse og/eller okning av kvinnelig libido | |
| ECSP088123A (es) | Anticoncepcion oral con trimegestona | |
| ES2693085T1 (es) | Uso de estriol en bajas dosis | |
| RS53876B1 (en) | PARENTERAL PHARMACEUTICAL FORM, WHICH RELEASES AROMATASE AND GESTAGEN BLOCKERS, FOR THE TREATMENT OF ENDOMETRIOSIS | |
| ECSP10010224A (es) | Formulaciones líquidas de hormona luteinizante (lh). | |
| CO6400186A2 (es) | Tabletas de acetato de ulipristal | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| CL2007003604A1 (es) | Composicion farmaceutica para administrar oral que comprende el compuesto 17-aminogeldanamicina amorfo; y su uso en el tratamiento del cancer. | |
| AR061959A1 (es) | Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas | |
| UY32650A (es) | Medicamento para la administración oral que contiene al menos un esterógeno y/o al menos un gestágeno y al menos una cepa de bacterias probióticas | |
| ECSP099482A (es) | Preparación farmacéutica para reducir la endometriosis | |
| GT200900296A (es) | Composición farmacéutica que comprende la combinación de un agente anti inflamatorio no esteroideo y un agente anticonvulsivante. | |
| CO2019000604A2 (es) | Composición vaginal que comprende una combinación de estrógeno y vitamina d | |
| AR053546A1 (es) | Forma farmacologica peroral solida para la anticoncepcion | |
| CU20090116A7 (es) | Preparación farmacéutica para reducir la endometriosis | |
| AR080541A1 (es) | Tratamiento para la endometriosis | |
| CU20110070A6 (es) | Método para tratar la endometriosis sin disminuir la densidad ósea | |
| CR9324A (es) | Preparación farmacéutica para la anticoncepción oral | |
| AR116592A1 (es) | Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib | |
| AR070023A1 (es) | Uso de gestagenos en combinacion con (6s)-5-metil-tetrahidrofolato para la terapia de la endometriosis con simultanea reduccion de los efectos colaterales terapeuticos asi como reduccion del riesgo de malformaciones congenitas al comenzar un embarazo | |
| DOP2007000122A (es) | Forma farmacologica peroral para anticoncepcion |